Navigation Links
SmithKline in Medical News

Iodex goes to SmithKline Beecham consumer Healthcare

Iodex is the market leader in the pain-balm segment, with a market share of 70 per cent-plus. Iodex faces challenges from local brands like Amrutanjan, Tiger Balm (locally manufactured by Elder Pharma), Zandu Balm and Sensur of Glenmark. // Glaxo SmithKline India (GSK) has decided to transfer...

New Cervical Cancer Vaccine to Be Launched By Glaxo Smithkline

Cervarix, a cervical cancer vaccine produced by Glaxo Smithkline (Britain's biggest drug manufacturer) is being registered for approval// by the European regulatory authority. If approved, the vaccine would be marketed for commercial use, by the end of next year. Gardasil, a similar vaccine ...

Cancer Patients Use New Guided Imagery CD to Help Boost Healthy Immune Functioning

... and hundreds of U.S. hospitals, including Mayo, Columbia Presbyterian, the Cleveland Clinic and Bethesda Naval Hospital. Pharmas such as Roche, Glaxo smithkline and Ortho Biotech have distributed over half a million CDs to Chemotherapy and Radiation patients around the English speaking world, and there are cur...

Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB

...xcellence in 2005. In 2004, IBC Conferences named him Chief Scientific Officer of the Year. Prior to joining Wyeth, Dr. Ruffolo spent 17 years at smithkline Beecham (now GSK) and 6 years at Lilly Research Laboratories. During his career, Dr. Ruffolo played a significant role in the discovery and/or develop...

Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer

...trategic planning and business development while at Inotek Pharmaceuticals Corp., Exact Sciences Corp., Pathogenesis Corp. (now part of Novartis), and smithkline Beecham (now part of GlaxoSmithKline). "I am looking forward to working with Dr. Celniker and the rest of the team that she has assembled as...

Watson Pharmaceuticals Reports Third Quarter 2008 Results

...ese forward-looking statements. Risperdal(R) is a registered trademark of Johnson & Johnson Corporation. Lamictal(R) is a registered trademark of smithkline Beecham Corporation. The following table presents Watson's results of operations for the three and nine months ended September 30, 2008 and 2007: ...

Smart Balance Announces Marketing Organization Appointment

...ountry's leading manufacturer of composite decking. Prior to that he held senior leadership roles with Mead Johnson/Bristol-Myers Squibb, Rite Aid and smithkline Beecham Consumer Healthcare. McWilliams has a BA from Westminister College and an MBA from Harvard Graduate School of Business. The Company issued t...

Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations

...cal Operations Manager for Scherer DDS (a division of RP Scherer) from 1994 to 1999; and various European clinical research positions with Beecham and smithkline Beecham and GH Besselaar from 1983-1994. Dr. Clarke holds a Bachelors of Science in Pharmacology from University of Sunderland and a PhD in Psychophar...

Memory Pharmaceuticals Appoints Paul Blake to Board of Directors

...esident, Worldwide Medical and Regulatory Operations. He has also served as Chief Medical Officer for MDS Proteomics, Inc. and as Medical Director for smithkline Beecham Pharmaceuticals, where he was responsible for its worldwide clinical research and development operations. "We are delighted to welcome Paul t...

Healthcare Veteran Richard Findlay Joins Diamond Management & Technology Consultants as Partner

...nagement & Technology Consultants, Inc. (Nasdaq: DTPI ) announced today that Richard Findlay, whose experience includes senior executive positions at smithkline Beecham and Abbott Laboratories, has joined the firm as a partner in its healthcare practice. Findlay has 25 years of experience in both managing and...

More>>

SmithKline in Medical Technology

Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results

...s over 27 years of clinical development experience, including previous positions at Avigenics Inc., Cephalon, Inc., MDS Proteomics, Inc. and smithkline Beecham Pharmaceuticals. Conference Call and Webcast Information Memory Pharmaceuticals will hold a conference call on March 6, 2008, at 9:00 a.m. ...
SmithKline in Biological Technology

Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors

...utive Team. Dr. Greig originally joined GSK (then smithkline & French) in 1980 in the Departments of Tumor ...d Human Genome Sciences. In 1996 Dr. Greig joined smithkline Beecham's European Pharmaceutical Operations as Vi...appointed Managing Director and General Manager of smithkline Beecham's UK Pharmaceuticals. Following the merge...

Transgenomic, Inc. Announces Appointment of New Board Members

...Drug Free workplace, plc, London, UK; ThauMDx LLC, Santa Barbara, CA; and International Cancer Screening Laboratories, Inc. Mr. McNulty previously ran smithkline Beecham's Chicago based reference laboratory prior to the company's transition to become Quest Diagnostics. In making this announcement, Transgen...

Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development

...is Post-Doctoral Fellowship at The Wistar Institute. Previous to joining Axial Biotech, Dr. Macina worked with the molecular diagnostics department at smithkline Beecham in the discovery and characterization of novel genes differentially expressed in different cancers. "Dr. Macina's decision to join Axia...

Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS

...itions in product development, R&D operations, corporate development and strategy, as well as new product research. Prior to Nektar, he worked at smithkline Beecham Pharmaceuticals in King of Prussia, PA, where he focused in the areas of pharmaceutical technology formulation sciences and product developmen...

GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.

... The solicitation and the tender offer to buy shares of Genelabs is only being made pursuant to the Offer to Purchase and related materials that GSK, smithkline Beecham Corporation and Gemstone Acquisition Corporation filed with the Securities and Exchange Commission (SEC) on November 12, 2008 and as subsequen...

GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.

...dated October 29, 2008 among Genelabs, Gemstone Acquisition Corporation and smithkline Beecham Corporation. All other terms and conditions of the tender o...eing made pursuant to the Offer to Purchase and related materials that GSK, smithkline Beecham Corporation and Gemstone Acquisition Corporation filed with the Sec...

GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc.

...being made pursuant to a previously announced Agreement and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone Acquisition Corporation and smithkline Beecham Corporation, a wholly-owned subsidiary of GSK. All other terms and conditions of the tender offer remain the same, including the condi...

GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.

...es. The tender offer is being made pursuant to a previously announced Agreement and Plan of Merger dated October 29, 2008 among Genelabs, Gemstone and smithkline Beecham Corporation, a wholly-owned subsidiary of GSK. The Genelabs board of directors has unanimously determined that the tender offer and the merg...

LF Elimination Program Treats Over Half Billion People and Protects Millions More From Debilitating Disease

...mbly unanimously resolved to eliminate the disease globally as a public health problem. In 1998, two pharmaceutical companies -- GlaxoSmithKline (then smithkline Beecham) and Merck & Co., Inc. -- partnered with WHO and pledged to donate two of the drugs necessary for LF elimination (albendazole and Mectizan(R),...

Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board

...isease research, biodefense and gene construction/expression. His previous experience includes assistant director, Department of Molecular Genetics at smithkline and French (now GlaxoSmithKline). About Lumiphore | Based in Richmond, California, Lumiphore is a biotechnology leader in the development of proprie...
Other Tags
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 As interest ... overall health care gains momentum worldwide, Rev. Eric J. ... HealthCare Chaplaincy Network (HCCN), will be the keynote speaker ... care in Israel’s public health system. , The conference, “Hope ...
(Date:1/22/2015)... released a new blog post presenting a list of vehicles that ... , Some types of vehicles cannot be covered under an ordinary ... to see if their vehicle qualifies for auto insurance coverage. ... cars that cannot be covered by a plan. Clients have little ...
(Date:1/22/2015)... 22, 2015 Step into a macabre ... Science Museum of Virginia. Wicked Plants, the Museum’s latest ... unearths 75 poisonous, carnivorous and diabolical plants inside of ... to uncover the biochemical, physical and neurological processes between ...
(Date:12/26/2014)... The US represents the largest market for CRC across the ... that sales of branded therapies were $2.23 billion. The US ... of the disease, high drug treatment rate, and higher drug ... of CRC therapies over the forecast period will be driven ...
(Date:12/26/2014)... Cooking and warming equipment has a buyer ... slightly positive negotiation conditions for buyers, stemming from a low ... level of price volatility. “However, buyer power is reduced by ... and high volatility in the world price of steel and ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
Other Contents